Combination of Superior Hypogastric Plexus Block and Transversus Abdominis Plane Block in Abdominal Hysterectomies

NCT07606781 | Recruiting

• 1 other identifier: 36265PR2/4/26
• Study Type: interventional
• Target: 44
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the analgesic effect of superior hypogastric plexus block combined with transversus abdominis plane block in abdominal hysterectomies.

Conditions

Superior Hypogastric Plexus Block; Transversus Abdominis Plane Block; Abdominal Hysterectomies

Outcome Measures

Primary Outcomes (1)

• Time to the first request for the rescue analgesia

  Time to the first request for the rescue analgesia will be recorded from the end of surgery to first dose of morphine administrated.

  24 hours postoperatively

Secondary Outcomes (4)

• Total morphine consumption

  24 hours postoperatively

• Degree of pain

  24 hours postoperatively

• Quality of recovery

  24 hours postoperatively

• Incidence of adverse events

  24 hours postoperatively

Study Arms (2)

Group S

EXPERIMENTAL

Patients will receive superior hypogastric plexus block (SHPB) using 20ml of bupivacaine 0.25%+ transverse abdominis plane (TAP) block using 20ml of bupivacaine 0.25%.

Other: Superior hypogastric plexus block + Transverse abdominis plane

Group C

ACTIVE COMPARATOR

Patients will receive superior hypogastric plexus block (SHPB) using 20ml of saline 0.9% (sham)+ transverse abdominis plane (TAP) block using 20ml of bupivacaine 0.25%.

Other: Superior hypogastric plexus block

Interventions

Superior hypogastric plexus block + Transverse abdominis plane OTHER

Patients will receive superior hypogastric plexus block (SHPB) using 20ml of bupivacaine 0.25%+ transverse abdominis plane (TAP) block using 20ml of bupivacaine 0.25%.

Group S

Superior hypogastric plexus block OTHER

Patients will receive superior hypogastric plexus block (SHPB) using 20ml of saline 0.9% (sham)+ transverse abdominis plane (TAP) block using 20ml of bupivacaine 0.25%.

Group C

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: Women undergoing abdominal hysterectomies
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years.
• American Society of Anesthesiology (ASA) physical status I-II.
• Undergoing abdominal hysterectomies under general anesthesia (GA).

You may not qualify if:

• History of allergies to local anesthetics.
• Body mass index (BMI) \>35 kg/m2.
• Opioid dependency.
• Cognitive impairment.
• Bleeding or coagulation disorders.
• Psychiatric and neurological disorder.
• Local infection at the site of injection.
• Severe heart, lung, liver, and renal dysfunction.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

RECRUITING

Central Study Contacts

Mohammed S Elsharkawy, MD

CONTACT

00201148207870; mselsharkawy@med.tanta.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.

Study Record Dates

• First Submitted: May 19, 2026
• First Posted: May 26, 2026
• Study Start: May 23, 2026
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: May 27, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)